Safety of 3-Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus-Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART-CHOICE Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yun, Kyeong Ho | - |
dc.contributor.author | Lee, Seung-Yul | - |
dc.contributor.author | Cho, Byung Ryul | - |
dc.contributor.author | Jang, Woo Jin | - |
dc.contributor.author | Song, Young Bin | - |
dc.contributor.author | Oh, Ju-Hyeon | - |
dc.contributor.author | Chun, Woo Jung | - |
dc.contributor.author | Park, Yong Hwan | - |
dc.contributor.author | Im, Eul-Soon | - |
dc.contributor.author | Jeong, Jin-Ok | - |
dc.contributor.author | Oh, Seok Kyu | - |
dc.contributor.author | Cho, Deok-Kyu | - |
dc.contributor.author | Lee, Jong-Young | - |
dc.contributor.author | Koh, Young-Youp | - |
dc.contributor.author | Bae, Jang-Whan | - |
dc.contributor.author | Choi, Jae Woong | - |
dc.contributor.author | Lee, Wang Soo | - |
dc.contributor.author | Yoon, Hyuck Jun | - |
dc.contributor.author | Lee, Seung Uk | - |
dc.contributor.author | Cho, Jang Hyun | - |
dc.contributor.author | Choi, Woong Gil | - |
dc.contributor.author | Rha, Seung-Woon | - |
dc.contributor.author | Lee, Joo Myung | - |
dc.contributor.author | Park, Taek Kyu | - |
dc.contributor.author | Yang, Jeong Hoon | - |
dc.contributor.author | Choi, Jin-Ho | - |
dc.contributor.author | Choi, Seung-Hyuck | - |
dc.contributor.author | Lee, Sang Hoon | - |
dc.contributor.author | Gwon, Hyeon-Cheol | - |
dc.contributor.author | Hahn, Joo-Yong | - |
dc.date.accessioned | 2022-01-24T00:40:31Z | - |
dc.date.available | 2022-01-24T00:40:31Z | - |
dc.date.issued | 2021-01 | - |
dc.identifier.issn | 2047-9980 | - |
dc.identifier.issn | 2047-9980 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/54113 | - |
dc.description.abstract | BACKGROUND: This study sought to investigate the safety of 3-month dual antiplatelet therapy (DAPT) in patients receiving ultrathin sirolimus-eluting stents with biodegradable polymer (Orsiro). METHODS AND RESULTS: The SMART-CHOICE (Smart Angioplasty Research Team: Comparison Between P2Y12 Antagonist Monotherapy vs Dual Anti- platelet Therapy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents) randomized trial compared 3-month DAPT followed by P2Y12 inhibitor monotherapy with 12-month DAPT in 2993 patients undergoing percutaneous coronary intervention. The present analysis was a prespecified subgroup analysis for patients receiving Orsiro stents. As a post hoc analysis, comparisons between Orsiro and everolimus-eluting stents were also done among patients receiving 3-month DAPT. Of 972 patients receiving Orsiro stents, 481 patients were randomly assigned to 3-month DAPT and 491 to 12-month DAPT. At 12 months, the target vessel failure, defined as a composite of cardiac death, target vessel-related myocardial infarction, or target vessel revascularization, occurred in 8 patients (1.7%) in the 3-month DAPT group and in 14 patients (2.9%) in the 12-month DAPT group (hazard ratio [HR], 0.58; 95% CI, 0.24-1.39; P=0.22). In whole population who were randomly assigned to receive 3-month DAPT (n=1495), there was no significant difference in the target vessel failure between the Orsiro group and the everolimus-eluting stent group (n=1014) (1.7% versus 1.8%; HR, 0.96; 95% CI, 0.41-2.22; P=0.92). CONCLUSIONS: In patients receiving Orsiro stents, clinical outcomes at 1 year were similar between the 3-month DAPT followed by P2Y12 inhibitor monotherapy and 12-month DAPT strategies. With 3-month DAPT, there was no significant difference in target vessel failure between Orsiro and everolimus-eluting stents. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | WILEY | - |
dc.title | Safety of 3-Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus-Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART-CHOICE Trial | - |
dc.type | Article | - |
dc.identifier.doi | 10.1161/JAHA.120.018366 | - |
dc.identifier.bibliographicCitation | JOURNAL OF THE AMERICAN HEART ASSOCIATION, v.10, no.1, pp 1 - 9 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000607087000001 | - |
dc.identifier.scopusid | 2-s2.0-85099428976 | - |
dc.citation.endPage | 9 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 1 | - |
dc.citation.title | JOURNAL OF THE AMERICAN HEART ASSOCIATION | - |
dc.citation.volume | 10 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | antiplatelet therapy | - |
dc.subject.keywordAuthor | coronary artery disease | - |
dc.subject.keywordAuthor | percutaneous coronary intervention | - |
dc.subject.keywordPlus | DURABLE-POLYMER | - |
dc.subject.keywordPlus | CLINICAL-OUTCOMES | - |
dc.subject.keywordPlus | LEADERS | - |
dc.subject.keywordPlus | EVENTS | - |
dc.subject.keywordPlus | THIN | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.